THE POTENTIAL PROTECTIVE ROLE OF AMINOGUANIDINE AND α-LIPOIC ACID IN

AMELIORATION OF CARBON TETRACHLORIDE-INDUCED HEPATOXICITY IN ALBINO RATS

Khaled A. Bayoumi, Alaa M. Shehab, Iman F. Gaballah and Ehab R. Ibrahim*

Departments of Forensic Medicine & Clinical Toxicology and Histology *, Faculty of Medicine, Cairo University

ABSTRACT

BACKGROUND: Carbon tetrachloride (CCl4) is a potent environmental hepatotoxin which is a well-known model compound for producing toxicity by generation of free radicals. HYPOTHESIS: It has been shown that aminoguanidine (AG) is a nitric oxide synthase inhibitor and α-lipoic acid (ALA) is a potent scavenger of a variety of free radicals. AIM: To determine the protective roles of aminoguanidine and lipoic acid against CCl4 hepatotoxicity in albino rats. MATERIALS AND METHODS: Male albino rats were randomly divided into five groups (8 rats/group). Groups I and II included normal control and CCl4 groups respectively; group III was given AG (100 mg/kg 2% solution in saline); group IV was given ALA (100mg/kg 1% solution in saline); group V was given AG and ALA in the same previously mentioned doses. Each of the groups III, IV and V received single oral daily dose of drugs for 2 weeks followed by concurrent administration of subcutaneous CCl4 (1 ml/kg) on alternate days for a week. Liver damage was depicted biochemically and histologically. RESULTS: Rats insulted with CCl4 showed significant reduction of hepatic function and marked alterations in the morphological changes of the liver. In addition, CCl4 violated the antioxidant status as evidenced by increase in lipid peroxidation in liver tissue as well as decrease reduced glutathione (GSH) and activities of superoxide dismutase (SOD) and catalase (CAT). Whereas pretreatment with either AG or ALA alone reduced these changes and attenuated the pathological effects of CCL4 induced liver injury, the combination of both drugs was better than each drug alone. CONCLUSION: These results clearly show that AG and / or ALA treatment significantly antagonize the effects of CCl4 on the liver. Therefore, these two components could be potential hepatoprotective agents.

KEY WORDS: Carbon tetrachloride; Aminoguanidine; Lipoic acid; Liver; Albino rats.

INTRODUCTION

Liver diseases are one of the most serious health problems in the world today but, despite great advances in modern medicine, their prevention and treatment lines still remain limited (Hussain et al., 2012). The liver is particularly

susceptible to chemically induced injury due to its extensive metabolic capacity and cellular heterogeneity. Oxidative stress occurs due to imbalance between reactive oxygen species (ROS) formation and scavenging by antioxidants. Excess generation of ROS can cause oxidative damage to biomolecules

resulting in lipid peroxidation and carcinogenesis (Khan and Sultana, 2009). Till date available modern drugs have not been able to come up with a satisfactory answer for liver disorders because of high cost and additional adverse effects. It is therefore necessary to search for alternative drugs for the treatment of liver diseases to replace the currently used drugs of doubtful efficacy and safety (Kumar et al., 2013).

Carbon tetrachloride (CCl4) is a colorless, volatile, heavy and nonflammable liquid well known for hepatic and renal toxic actions. The metabolism of CCl4 into trichloromethyl and peroxy trichloromethyl free radicals has been reported to cause liver cirrhosis, steatosis and necrosis (Weber et al., 2003). Furthermore, CCl4 treatment has been used as a model to induce fatty liver for studying possible interacting effects of a compound or a treatment (Recknagel, 1967). It should be noted that CC14 produces an experimental damage that histologically resembles viral hepatitis (James and Pickering, 1976).

Aminoguanidine (AG) is an antioxidant substance that acts as a competitive and selective inhibitor for inducible nitric oxide synthase (iNOS) (Ara et al., 2006). Nitric oxide (NO) is an important mediator of hepatotoxicity (Hortelano et al., 1999). It is derived from two sources in liver. Hepatocytes and Kupffer cells contain (iNOS), the activity of which is markedly increased in inflammation. Endothelial cells

contain constitutive NO synthase (eNOS). Nitric oxide is known to react with superoxide radical, forming the more potent oxidizing agent peroxynitrite (ONOO-) (Ischiropoulos et al., 1992). The latter can react directly with sulfhydryl residues in the cell membranes leading to lipid peroxidation as well as with DNA resulting in cytotoxicity (Radi et al., 1991). The enzyme iNOS is expressed during the development of cirrhosis. Therefore, the prevention of iNOS expression may have an important role in both cirrhosis and endotoxaemia (Heller et al., 2000). The action of AG has been known to be associated with reduction of peroxinitrite, which has deleterious roles in inductions of inflammation, lipid peroxidation and DNA fragmentation (Potenza et al., 2009). Previous investigations have also demonstrated that AG reduced hydrogen peroxide (H2O2) induced intracellular hydroxyl radical formation and apoptosis, further demonstrating a potential antioxidant activity (Ihm et al., 1999). AG protection could be through decreasing the metabolic activation of CC14 by directly inhibiting P4502E1, the isoenzyme most effective in the activation of CC14 (Doglru-Abbasogllu et al., 2002).There are conflicting data in the literature to support both a protective and a cytotoxic role of NO in liver and kidney (Gardner et al., 2002; Li et al., 2003 and Liu et al., 2003). Furthermore, pretreatment with the selective iNOS inhibitor, AG, protects

against hepatotoxicity induced by endotoxin (Shiomi et al., 1998) or hepatotoxic agents as paracetamol (Gardner et al., 2002) and results in renal failure improvement in cirrhotic rats (Islas-Carbajal et al., 2005). Alpha lipoic acid (ALA) has become one of the most recognized and in-demand health supplements. It is a naturally occurring, short-chain fatty acid containing two sulfur molecules. ALA is both water and fat soluble and, therefore, is distributed in both the cellular membranes and the cytosol in plants and animals (Wollin & Jones, 2003). ALA plays an essential role in mitochondrial dehydrogenase reactions (Packer et al., 1997) and has found considerable attention as a very potent antioxidant that fights free radicals and improves recovery (Moini et al., 2002). Due to its readily absorption throughout the body, it may protect the integrity of cells ranging from the brain to the liver (Keith et al., 1997). It shows beneficial effects in oxidative stress conditions because of its synergistic action with other antioxidants (Suzuki et al., 1993). ALA is taken up and reduced by cells to dihydrolipoic acid (DHLA), which can be released into the extracellular medium (Arner et al., 1996). ALA and DHLA can serve as powerful antioxidants through several mechanisms, including scavenging of free radicals, chelation of metal ions, and regeneration of endogenous and exogenous antioxidants, such as ubiquinon, vitamins C and E, and glutathione (Kozlov et al., 1999). There is growing evidence that

orally delivered ALA may not be used as a metabolic cofactor but, instead, has a unique property of neutralizing free radicals without itself being consumed in the process (Shay et al., 2009).

Given that oxidative stress plays a basic role in CCl4 hepatotoxicity, the present study was undertaken to explore the influence of AG and/or ALA on CCl4 induced hepatic toxicity. To this end, the antioxidant and the radical scavenging activities of AG and ALA were evaluated by estimating the activities of glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), as well as the extent of lipid peroxidation in the liver tissue. In addition, the study also examined the protective effects of AG and/or ALA on liver functions in CCl4 intoxicated rats. To our knowledge no report is available until now, for the protective action of combined aminoguanidine and lipoic acid on CCl4-induced toxicity in vivo.

MATERIALS AND METHODS

Experimental Animals: Random – bred, adult male

albino rats (Wistar strain) weighing approximately 125 – 150 gm were obtained from the Animal House of National Research Centre, Dokki, Cairo, Egypt. Animals were evaluated prior to initiation of the study to ensure a healthy condition and acclimation to the study environment. Clinically acceptable animals were randomly assigned into 5 groups (8 animals / group), so that there were no statistically

significant differences among group body weight means. Four animals were housed in each stainless steel wire mesh cage on a bedding of wood chips at constant temperature of 25 ± 2o C, illumination (12 h light/dark) and had free access to commercial food and tap water, ad libitum and left for an initial adaptation period of 1 week before any experimental manipulation.

All animals received human care according to the criteria outlined in “Guide for the care and use of laboratory animals” prepared by the National Academy of Sciences and published by the National Institute of Health.

Test Materials: Aminoguanidine, alpha-lipoic acid were purchased from Sigma, St. Louis, MO, USA. Carbon tetrachloride (CCl4) was obtained from Egyptian company for chemicals and pharmaceuticals (ADWIA). Biochemical kits were purchased from the Gamma Trade Company for Pharmaceutical and Chemicals, Dokki, Egypt.

Experimental groups:Rats were randomly divided into:Group I rats served as normal (vehicle) control and received oral saline at equivalent volume of that of the test drugs in the presence of 0.05 mol/l NaOH for 2 weeks followed by concurrent subcutaneous (sc) administration of liquid Paraffin (LP) in the lower abdomen 1 ml/ kg on alternate day for one week; group II rats were given oral saline at equivalent volume of that of the test drugs in the presence of 0.05 mol/l NaOH

for 2 weeks followed by concurrent administration of carbon tetrachloride (CCl4) subcutaneously (sc) in the lower abdomen, in a suspension of liquid paraffin (1: 2 v/v) at the dose of 1 ml/kg BW on alternate days for a week for induction of hepatotoxicity (Achilya et al., 2003); group III was given aminoguanidine (AG) (100 mg/kg 2% solution in saline) (Ahmed et al., 2011) ; group IV was given alpha lipoic acid (ALA) (100mg/kg 1% solution in saline in the presence of 0.05 mol/l NaOH) (Pari and Murugavel, 2004); group V was given AG and ALA in the same previously mentioned doses. Groups (III, IV and V) received single oral daily dose of drugs through a gastric tube for 2 weeks followed by concurrent administration of CCl4 on alternate days for a week. Different doses of above mentioned drugs, LP and CCl4 were administered to rats daily in the morning according to the ethical guidelines for the care of the laboratory animals (Zimmerman, 1983). Two hours after the last administration, blood samples were collected by cardiac puncture under chloral hydrate (6 ml. of 7 % chloral hydrate / kg, Sigma, St. Louis, USA) anesthesia. Blood samples were placed in heparinized tubes, allowed to clot and centrifuged at 3000×g for 10 min to obtain sera which were used to determine SGOT, SGPT, SALP and total bilirubin. Immediately after blood collection, the animals were scarified by cervical dislocation and liver specimens were promptly

removed and perfused with phosphate buffer solution (PBS) [PH = 7.4] containing 0.16 mg/ml heparin. Then livers were isolated and dissected into 2 parts. The first part was taken and placed in 10% neutral formalin, dehydrated in ascending series of ethanol, cleared in xylol and then embedded in paraffin for histopathological examination.The second part was immersed immediately in liquid nitrogen and kept at -80o C for determination of malondialdehyde (MDA), reduced glutathione (GSH), contents, superoxide dismutase (SOD) and catalase (CAT).

Clinical chemistry:

Serum biochemical estimations:Estimation of total bilirubin

“mg/dl” (Perry et al., 1983); glutamic oxalacetic transaminase (SGOT) “unit/dl” and glutamic pyruvic transaminase (SGPT) “unit/dl” (Reitman and Frankel, 1975) and alkaline phophatase (SALP) “unit/l” (Tietz and Rinker, 1983).

Liver biochemical estimations: The levels of lipid peroxidation i.e. thiobarbituric acid reactive substances (TBARS) in the liver tissue were measured according to Okhawa et al., (1979). The levels of lipid peroxides were expressed as μmoles of malondialdehyde (MDA)/g of liver tissue. The reduced glutathione (GSH) content of liver tissue was determined as per reported method of Ellman, (1959) and expressed as μg/g of liver tissue. The superoxide

dismutase (SOD) and catalase (CAT) activities in liver tissue were assayed as per the methods of Kakkar et al., (1984) and Aebi, (1974) respectively. The SOD activity was expressed as unit/mg of liver tissue and CAT was expressed in terms of μmol of hydrogen peroxide decomposed/min/mg of liver tissue. Histopathology:

Liver sections of 6 microns thick were prepared and stained with haematoxylin and eosin (Drury and Wallington, 1980). The extent of liver damage was assessed under light Olympus microscope.

Statistical analysis:The data were analyzed

using IBM computer and SPSS- P.C 4.1 statistical package. All results were expressed as the mean ± standard error of mean (SEM). They were analyzed for statistical significance by one-way ANOVA followed by Dunnett's post hoc test of significance. P < 0.05 was statistically significant.

RESULTS

Number of deaths of animals:We started the study with 8 rats/normal control group and 14 rats/CCl4 group. Groups III, IV and V were 10 rats/group. In CCl4 group, 6 rats died while in the treatment groups 2 rats died and the extreme values were excluded giving 8 rats/group used for statistical analysis.Serum biochemical parameters: there were significant elevations (p

< 0.001) of SGOT, SGPT, SALP and serum bilirubin in the CCl4 group as compared to the normal control group. Treatment with AG, ALA or both significantly (p < 0.001) reduced the SGOT, SGPT, SALP and serum bilirubin levels towards the normal values (Table 1). Rats of Group-V showed comparable SGOT, SGPT, SALP and serum bilirubin levels to that of normal control rats.

Liver biochemical parameters: Treatment of rats with CCl4 increased lipid peroxidation as evident by significant rise (p < 0.001) in the levels of MDA in CCl4 animals as compared to normal control group. Treatment with AG, ALA or both significantly (p < 0.001) reduced the MDA levels when compared with CCl4 animals (Table 2). Significant depletion in the level of GSH was noticed in CCl4 group (p < 0.001) as compared with normal control group. Significant elevation in GSH level towards normal level occurred on administration of AG (p < 0.05) and ALA or combination of AG & ALA (p < 0.001) as compared with CCl4 group (Table 2). There were significant (p < 0.001) decrease in SOD and CAT activities in CCl4 group compared with normal control group. Administration of AG (p < 0.05) and ALA or combination of AG & ALA (p < 0.001) significantly restored SOD and CAT activities towards normal values when compared with CCl4 animals (Table 3).

Histopathological Results:

Liver sections of control rats showed the normal histological structure of hepatic lobules (Figure 1). Livers challenged with CCl4 showed centrilobular hepatocellular necrosis, marked fatty and cellular infiltration (Figure 2). However, pretreatment with either AG or ALA resulted in partial improvement of hepatocytes and preserved hepatic architecture (Figures 3 & 4), while pretreatment with both drugs together resulted in marked improvement in the hepatic architecture nearly to the control groups (Figure 5).

DISCUSSION

Deaths due to hepatic disorders are increasing in number and there is only limited number of drugs available for the treatment. Currently the researchers across the world are focusing their attention to develop an ideal hepatoprotective agent. Since reactive oxygen species are very important causes of liver damage, an antioxidant may be a useful tool for protecting the liver cells (Jain et al., 2008).

In the present study, CCl4 caused a significant increase in the mean values of SGPT, SGOT, SALP and serum bilirubin. Plasma membrane, endoplasmic reticulum, mitochondria, and Golgi apparatus are the main subcellular structures affected by CCl4 exposure. Damage to plasma membrane of hepatocytes results in release of enzymes in circulation (Reynolds, 1963). On the other hand, serum bilirubin levels reflect the functional state of hepatic cells (Gupta et al., 2004). These results are in accordance with

previous studies by Drotman & Lawhorn (1978); Mukherjee (2003); Weber et al., (2003); Soni et al., (2008); Karwani & Sisodia (2011) and Feroz et al., (2013). Kumar et al., (2013) reported similar results but the rise in bilirubin level was not to the same extent as SGPT, SGOT and SALP. This could be explained by the fact that blood collection in Kumar et al., (2013) study was 24 hours after CCl4 administration while bilirubin reaches peak serum level in the second hour after CCl4 administration and probably declines afterwards (Gumucio, 1989). The findings of the present study indicated that hepatic injury was reduced by aminoguanidine (AG) or alpha lipoic acid (ALA) drugs with a reduction in plasma levels of SGOT and SGPT as well as the cell membrane enzyme SALP and serum total bilirubin. The study also indicated the usefulness of combining both AG and ALA. The protective effect of AG against the enzyme leakage seems to be through the liver cell membrane integrity restoration and is independent of any effects on liver GSH contents (Raza et al., 2003). It is noteworthy that ALA protects the liver against CCl4 toxicity by regenerating endogenous antioxidants and inhibiting the elevation of liver aminotransferases (Morakinyo et al., 2012). These results are in agreement with the results obtained by Raza et al., (2003) and Ahmed et al., (2011), who illustrated the hepatoprotective effect of AG and Sivaprasad et al., (2004); Abdel-Zaher et al., (2008);

Foo et al., (2011) and Morakinyo et al., (2012) who demonstrated the ALA hepatoprotective effects. In contrast, AG treatment against CCl4 induced hepatoxicity was ineffective in reducing the leakage of hepatic enzymes according to reports of some other investigators (Skamarauskas et al., 1996 and Kamel et al., 2011). This opposition may be explained on the basis of using different dose regimens. The present study revealed increased lipid peroxidation as evidenced by a significant rise in liver MDA and significant decrease in superoxide dismutase (SOD) and catalase (CAT) activities in CCl4 treated rats. This enhanced lipid peroxidation results in tissue damage and failure of antioxidant defense mechanisms (Ashok et al., 2001). SOD and CAT are endogenous enzymatic antioxidants present in all oxygen metabolizing mammalian cells involved in the clearance of superoxide and hydrogen peroxide (H2O2) , so each of them is an index of increased H2O2 production (Meneghini, 1997). GSH, one of the major tripeptide non-enzymatic biological hepatic antioxidants, is involved in removal of free radicals and a substrate for glutathione peroxidase. Deficiency of GSH within the living organisms can lead to tissue damage and injury (Leeuwenburgh and Ji, 1995). A significant decrease in liver GSH was observed in CCl4 treated rats in the present study. This may be due to enhanced substrate utilization by glutathione peroxidase, as there is a direct correlation between GSH

depletion and enhanced lipid peroxidation (Al-Shabanah et al., 2000). Numerous studies reported similar rise in MDA (Pramod et al., 2008; Soni et al., 2008; Neetu & Sangeeta, 2010 and Taye & Abdel-Raheem, 2012) and decrease in SOD, CAT and GSH (Lin et al., 2008 and Dikshit et al., 2011) on CCl4 intoxication.

The present study demonstrated that administration of AG and/or ALA prior to CCl4 protected against the oxidative stress and liver damage. This suggested an alternative mechanism of AG protection via decreasing the metabolic activation of CC14 by direct inhibition of the isoenzyme most effective in the activation of CC14, namely P4502E1, (Doglru-Abbasogllu et al., 2002). Thus decreasing the free radicals release that causes lipid peroxidation (Mustafa et al., 2002). The ameliorating action of ALA against CCl4-induced lipid peroxidation is due to its free-radical scavenging properties (Di Stefano et al., 2006). ALA can scavenge hydroxyl radicals, hypochlorous acid, singlet oxygen, peroxynitrite, and nitric oxide (Biewenga et al., 1997 and Moini et al., 2002). In addition, ALA can regenerate endogenous antioxidants in the body including vitamin C, vitaminE and intracellular reduced glutathione (GSH) (Biewenga et al., 1997). Our study coincides with earlier works that demonstrated antioxidant hepatoprotective potential of AG (Ahmed et al., 2011) and ALA (Arivazhagan et al., 2001). Not in agreement with our data,

Selvakumar et al., (2004) reported that after administration of ALA at a dose of 35 mg/ kg body weight, no significant difference in the activation of antioxidant enzymes was observed between the treated group and the control group.

Parallel to the biochemical alterations in this current study, CCl4 induced numerous histological variations in the liver in the form of hepatocellular necrosis and massive fatty and cellular infiltration. However, administration of AG and/or ALA attenuated the degree of tissue damage. Histophathological results which support the results of biochemical parameters are the in-situ evidence of hepatoprotective effects of AG and ALA.

CONCLUSION & RECOMMENDATIONS

Our results support the protective effect of aminoguanidine and / or α-lipoic acid supplementation in reducing hepatotoxic hazards due to exposure to carbon tetrachloride in albino rats as evidenced by biochemical and histological studies. However, the simultaneous use of both drugs has a more beneficial effect than the use of either of them alone.

This implies the potential usefulness of both aminoguanidine and α-lipoic acid as dietary supplements for populations at risk for liver damage as cases of viral hepatitis- which produces histological damage similar to that of CCl4 “of course after extensive research work on humans”.

FUTURE RESEARCH WORK:

Further studies on different dose schedules and time – intervals might be needed to achieve the best results. Also, further research work/s will be needed to elucidate the exact mechanism/s by which AG and / or ALA protect against CCl4 – induced hepatotoxicity.

ABBREVIATIONS ALA: α- lipoic acid. CAT: catalase. CCl4: carbon tetrachloride. DHLA: dihydrolipoic acid. eNOS: endothelial nitric oxide

synthase. GSH: reduced glutathione. H2O2: hydrogen peroxide. iNOS: inducible nitric oxide

synthase.

LP: liquid Paraffin. malondialdehyde (MDA) NO: nitric oxide. ROS: reactive oxygen species. SALP: serum alkaline

phosphatase. SGOT: serum glutamic

oxalacetic transaminase. SGPT: serum glutamic

pyruvic transaminase. SOD: superoxide dismutase. TBARS: thiobarbituric acid

reactive substances.CONFLICT OF INTEREST

STATEMENTThe authors declare that they have no conflict of interest.

Table (1): Mean values of liver function tests in the studied groupsGroupSGOT

IU/LSGPTIU/L

SALPIU/L

Total bilirubinMg/dl

Group I24.97 ± 3.2220.66 ± 5.209.82 ± 0.730.52 ± 0.07Group II85.55 ± 2.37#84.66± 10.72#22.46± 3.10#2.04± 0.34#

Group III44.49± 2.49**40.66± 5.45**14.28± 0.26**0.67± 0.11**Group IV38.54± 1.55**33.33± 2.40**11.42± 0.08**0.63± 0.13**Group V31.62± 1.51**34.66± 5.81**11.53± 0.44**0.59± 0.15**

Values are mean ± SEM. Carbon tetrachloride group [group II] vs. normal control group [group I], #p < 0.001. Treated groups vs. carbon tetrachloride group, **p< 0.001; *p < 0.05 where the significance was performed by one-way analysis of variance (ANOVA) followed by Dunnett’s test.

Table (2): Lipid peroxidation and reduced glutathione (GSH) in livers of the studied groups.

GroupMDA (µmol/g liver tissue)GSH (µg/g liver tissue)Group I40.41 ± 3.2723.88 ± 1.71Group II91.66 ± 1.90#11.81± 0.68#

Group III58.95± 3.83**16.47± 1.28*Group IV43.95± 1.04**20.97± 1.74**Group V39.37± 2.58**22.53± 3.01**

Values are mean ± SEM. Carbon tetrachloride group [group II] vs. normal control group [group I], #p < 0.001. Treated groups vs. carbon tetrachloride group, **p<

0.001; *p < 0.05 where the significance was performed by one-way analysis of variance (ANOVA) followed by Dunnett ’ s test.

Table (3): Superoxide dismutase (SOD) and catalase (CAT) activities in livers of the studied groups.

GroupSOD (IU/mg liver tissue)CAT (µmol of H2O2 decomposed/min/mg)

Group I7.93 ± 0.292.8 ± 0.13Group II3.73 ± 0.20#0.97± 0.20#

Group III5.22 ± 0.33*1.64 ± 0.21*Group IV6.76 ± 0.49**3.07 ± 0.28**Group V6.48 ± 0.67**2.21 ± 0.42**

Values are mean ± SEM. Carbon tetrachloride group [group II] vs. normal control group [group I], #p < 0.001. Treated groups vs. carbon tetrachloride group, **p< 0.001; *p < 0.05 where the significance was performed by one-way analysis of variance (ANOVA) followed by Dunnett ’ s test.

Figure (1): Normal histological structure of hepatic lobules - normal control group (H & E X200).

Figure (2): Animals exposed to CCl 4 showing centrilobular hepatocellular necrosis, fatty degeneration [white arrows] and cellular infiltration [black arrows] (H & E X600)

Figure (3): Animals exposed to CCL4 and pretreated aminoguanidine showing congestion [black arrow] and moderate cellular infiltration [white arrow] (H & E X100).

Figure (4): Animals exposed to CCL4 and pretreated alpha lipoic acid showing congestion [black arrow] (H & E X200).

Figure (5): Animals exposed to CCL4 and pretreated with both aminoguanidine and alpha lipoic acid (H & E X200).

REFERENCES

Abdel-Zaher, A. O.; Abdel-Hady, R. H.; Mahmoud, M. M. and Farrag, M. M. (2008): The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicol., 243: 261-270..

Achilya, G. S.; Kotagale, N. R.; Wadokar, S. G. and Dorle, K. (2003): Hepatoprotective of panchegava ghirta against carbon

tetrachloride in rats. Indian J. Pharmacol., 35: 308.

Aebi, H. (1974): Catalase. In: Methods in Enzymatic Analysis. Vol. II. (Packer, L., ed.), Academic Press, New York, p.p.: 673-684.

Ahmed, F.; Mona, F.; Marwa, A.; and Eman, A. (2011): Aminoguanidine potentiates the hepatoprotective effect of silymarin in CCL4 treated rats. Ann. Hepatol., 10(2):207-215.

Al-Shabanah, O.A.; Alam, K.; Nagi, M.N.; Al-Rikabi, A.C. and Al- Bekairi, A.M. (2000): Protective effect of aminoguanidine, a nitric oxide synthase inhibitor, against carbon tetrachloride induced hepatotoxicity in mice. Life Sci., 66: 265-270.

Ara, C.; Karabulut, A.B.; Kirimlioglu, H.; Yilmaz, M.; Kirimliglu, V. and Yilmaz, S. (2006): Protective effect of aminoguanidine against oxidative stress in an experimental peritoneal adhesion model in rats. Cell Biochem. Funct., 24(5):443-448.

Arivazhagan, P.; Ramanathan, K. and Panneerselvam, C. (2001): Effect of DL-alpha lipoic acid on mitochondrial enzymes in aged rats. Chem. Biol. Interact., 138:189-198.

Arner, E. ; Nordberg, J. and Holmgren, A. (1996): Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem. Biophys. Res. Commun., 225: 268–274.

Ashok, S.h.K.; Somayaji, S.V. and Bairy, K.L. (2001): Hepatoprotective effects of Ginkgo biloba against carbon tetrachloride induced hepatic injury in rats. Ind. J. Pharmacol., 33: 260-266.

Biewenga, G.P.; Haenen, G.R. and Bast, A. (1997): The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol. 29: 315–331.

Dikshit, P.; Tyagi, M.K.; Shukla, K; Sharma, S.; Gambhir, J.K.

and Shukla, R. (2011): Hepatoprotective effect of stem of Musa sapientum Linn in rats intoxicated with carbon tetrachloride. Ann. Hepatol. 10(3):333-339.

Di Stefano, A.; Sozio, P. and Cocco, A. (2006): L-Dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J. Med. Chem., 49:1486–1493.

Doglru-Abbasogllu, S.; Balkan, J.; Cevikbas, U.; Aykac-Toker, G. and Uysal, M. (2002): Aminoguanidine, an inducible nitric oxide synthase inhibitor, plus N- acetylcysteine treatment reduce the lipopolysaccharide-augmented hepatotoxicity in rats with cirrhosis. Hum. Exp. Toxicol., 21: 359-364.

Drotman, R.B. and Lawhorn, G.T. (1978): Serum enzymes as indicators of chemical induced liver damage. Drug Chem. Toxicol., 1:163–171.

Drury, R.A.B. and Wallington, E.A. (1980): Histological technique, 4th ed., Oxford University Press, New York, Toronto, P.P. 8 – 11.

Ellman, G.L. (1959): Tissue sulphydryl groups. Arch. Biochem. Biophys., 82: 70-72.

Feroz, Z.; Khan, R. A.; Amber, A. and Mahayrookh, M. (2013): Hepatoprotective effect of herbal drug on CCl4 induced liver damage. Pak. J. Pharm. Sci., 26(1): 99–103.

Foo, N.; Lin, S.; Lee, Y.; Wu, M. and Wang, Y. (2011): α-Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF- beta. Toxicol., 282: 39–46.

Gardner, C.R.; Laskin, J.D.; Dambach, D.M.; Sacco, M.; Durham, S.K.; Bruno, M.K.; Cohen, S.D.; Gordon, M.K.; Gerecke, D.R.; Zhou, P., and Laskin, D.L. (2002): Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interleukin-10. Toxicol. Appl. Pharmacol., 184: 27–36.

Gumucio, J.J. (1989): Hepatocyte heterogeneity: The coming of age from the description of a biological curiosity to a partial understanding of its physiological meaning and regulation. Hepatol., 9: 154–160.

Gupta, Y.K.; Sharma, M.; Chaudhary, G. and Katiyar, C.K. (2004): Hepatoprotective effect of New Livfit, a polyherbal formulation, is mediated through its free radical scavenging activity. Phytother. Res., 18: 362–364.

Heller, J.; Sogni, P. and Barriere, E. (2000): Effects of lipopolysaccharide on TNF-α production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J. Hepatol., 33: 376-381.

Hortelano, S.; López-Collazo, E. and Bosc, L. (1999): Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br. J. Pharmacol., 126: 1139-1146.

Hussain, T.; Gupta, R. K; Sweety, K.; Khan, M. S.; Hussain, M.S.; Hussain, A.; Faiyazuddin, M. and Rao, C. V. (2012): Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatotoxicity in experimental rodents. Asian Pac. J. Trop. Biomed., 454-460.

Ihm, S.H.; Yoo, H.J.; Park, S.W. and Ihm, J. (1999): Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism, 48(9):1141-1145.

Ischiropoulos, H.; Zhu, L. and Beckman, J. S. (1992): Peroxynitrite formation from macrophage-derived nitric oxide. Arch. Biochem. Biophys., 298: 446-451.

Islas-Carbajal, M.C.; Covarrubias, A.; Grijalva, G.; Alvarez-Rodriguez, A.; Armendariz-Borunda, J. and Rincon-Sanchez, A.R., (2005): Nitric oxide synthases inhibition results in renal failure improvement in cirrhotic rats. Liver Int. 25: 131–140.

Jain, A.; Soni, M.; Deb, L.; Rout, S.P.; Gupta, V.B. and Krishna, K.L. (2008): Antioxidant and hepatoprotective activity of

ethanolic and aqueous extracts of Momordica dioica Roxb. Leaves. J. Ethnopharmacol., 115: 61-66.

James, G.W. and Pickering, R.W. (1976): The protective effect of a novel compound RU 18492, on galactosamine induced hepatotoxicity in the rat. Drug Res., 26(12): 2197-2180.

Kakkar, P.; Das, B. and Vishwanath PN. (1984): A modified spectrophotometric assay of superoxide dismutase. Indian J. Biochem. Biophys., 21: 130-132.

Kamel, H.H.; Azza, H.A.; Walaa, M.S. and Amira, H.M. (2011): Protective Effect of some Antioxidants against CCl4-Induced Toxicity in Liver Cells from BRL3A Cell Line. J. Am. Sci., 7(2): 283 – 296.

Karwani, G. and Sisodia, S. (2011): Hepatoprotective activity of Mimosa Pudica Linn. in carbon tetrachloride induced hepatotoxicity in rats. J. Herb. Med. Toxicol., 5(1): 27 – 32.

Keith, R.L.; Setiarahardjo, I.; Fernando, Q.; Aposhian, A.J. and Gandolfi, A.J. (1997): Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney. Toxicology 116: 67-75. Khan, T. and Sultana, S. (2009): Antioxidant and hepatoprotective potential of Aegle marmelos Correa against CCl4- induced oxidative stress and early tumor events. J.

Enzyme Inh. Med. Chem., 24 (2): 320-327.

Kozlov, A. V.; Gille, L.; Staniek, K. and Nohl, H. (1999): Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch. Biochem. Biophys., 363: 148–154.

Kumar, V.; Modi, P.K. and Saxena, K.K. (2013): Exploration of hepatoprotective activity of aqueous extract of Tinospora Cordifolia- an experimental study. Asian. J. Pharm. Clin. Res., 6(1): 87–91.

Leeuwenburgh, C. and Ji, L.L. (1995): Glutathione depletion in rested and exercised mice: Biochemical consequence and adaptation. Arch. Biochem. Biophys., 316(2): 941-949.

Li, C.; Liu, J.; Saavedra, J.E.; Keefer, L.K. and Waalkes, M.P. (2003): The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen- induced nephrototoxicity in mice. Toxicol. 189: 173–180.

Lin, H.; Tseng, H.; Wang, C.; Lin, G.; Lo, C. and Chou, F. (2008): Hepatoprotective effects of Solanum nigrum Linn extract against CCl4-iduced oxidative damage in rats. Chem. Biol. Interact. 171: 283–293.

Liu, J.; Li, C.; Waalkes, M.P.; Clark, J.; Myers, P.; Saavedra, J.E. and Keefer, L.K., (2003): The

nitric oxide donor,V-PYRRO/NO, protects against acetaminophen- induced hepatotoxicity in mice. Hepatology 37: 324–333.

Meneghini, R. (1997): Iron homeostasis, oxidative stress, and DNA damage. Free Radical Biol. Med., 23 (5): 783–792.

Moini, H.; Packer, L. and Saris, N. (2002): Antioxidant and prooxidant activities of alpha-lipoic acid. Toxicol. Appl. Pharmacol., 182: 84-90.

Morakinyo, A.O.; Oludare, G.O.; Anifowose, A.A. and Adegoke, O.A. (2012): Protective Effects of Alpha Lipoic Acid on Carbon Tetrachloride-Induced Liver and Kidney Damage in Rats. Br. J. Pharmacol. Toxicol, 3(1): 21-28.

Mukherjee, P.K. (2003): Plant products with hypocholesterolemic patientials, Adv. Food Nutr. Res., 47: 277–338.

Mustafa, A., Gado, A.M.; Al-Shabanah, O.A. and Al-Bekairi, A.M. (2002): Protective effect of aminoguanidine against paraquatinduced oxidative stress in the lung of mice. Comp. Biochem. Physiol. Part C, 132: 391-397.

Neetu, S. and Sangeeta, S. (2010): Hepatoprotective potential of aqueous extract of Butea monosperma against CCl4 induced damage rats. Exp. Toxicol. Pathol. Doi.: 10.1016/ j.etp.2010.05.009.

Okhawa, H.; Oishi, N. and Yagi, K. (1979): Assay for lipid

peroxides in animal tissue by thiobarbituric acid reaction. Anal. Biochem., 95: 351-358. Packer, L.; Tritschler, H.J. and Wessel, K. (1997): Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic. Biol. Med., 22(1-2):359-378.

Pari, L.; Murugavel, P. (2004): Protective effect of alpha-lipoic acid against chloroquine-induced hepatotoxicity in rats. J. Appl. Toxicol., 24: 21-26.

Perry, B.W.; Doumas, B.T. and Bayse, D.D.(1983): A candidate reference method for determination of bilirubin in serum test for transferability. Clin. Chem., 29:297-301.

Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. (2009): Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr. Med. Chem., 16(1):94-112.

Pramod, K.; Deval, R.G.; Lakshmayy, A. and Ramachandra, S.S. (2008): Antioxidant and hepatoprotective activity of tubers of Momordica tuberosa against CCl4 induced liver injury in rats. Indian J. Exp. Biol., 46: 510-513.

Radi, R.; Bechman, J.S.; Bush, K.M. and Freeman, B.( 1991): Peroxynitrite Oxidation of Sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem., 266(7): 4244-4250.

Raza, M.; Ahmad, M.; Gado, A. and Al-Shabanah, O. A. (2003): A comparison of hepatoprotective activities of aminoguanidine and N-acetylcysteine in rat against the toxic damage induced by azathioprine. Comp. Biochim. Physiol. Part C; 134: 451-456.

Reitman, S. and Frankel, S. (1975): Colourimetric method for the determination of SGOT and SGPT. Am. J. Clin. Pathol., 28: 58-61.

Reynolds, E.S. (1963): Liver parenchymal cell injury. Initial alteration of the cell following poisoning with carbon tetrachloride. J. Cell Biol., 19: 139-157.

Rscknagel, R.O. (1967): Carbon tetrachloride hepatotoxicity. Pharmacol. Rev. 19: 145-195.

Selvakumar, E.; Prahalathan, C.; Mythili, Y. and Varalakshmi, P. (2004): Protective effect of DL-a-lipoic acid in cyclophosphamide induced oxidative injury in rat testis. Reprod. Toxicol., 19:163-167.

Shay, K.P.; Moreau, R.F.; Smith, E.J.; Smith, A.R. and Hagen, T.M. (2009): Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 1790: 1149–1160.

Shiomi, M.; Wakabayashi, Y.; Sano, T.; Shinoda, Y.; Nimura, Y. and Ishimura, Y. (1998): Nitric oxide suppression reversibly attenuates mitochondrial

dysfunction and cholestasis in endotoxemic rat liver. Hepatol. 27: 108–115.

Sivaprasad, M.; Nagaraj, P. and Varalakshmi, P. (2004): Combined efficacies of lipoic acid and 2,3-dimercaptosuccinic acid against lead-induced lipid peroxidation in rat liver. J. Nutr. Biochem., 15: 18–23.

Skamarauskas, J.; McKay, A. and Hunt, J. (1996): Aminoguanidine and its prooxidant effects on an experimental model of protein glycation. Free Rad. Biol. Med., 21: 801–812.

Soni, B.; Visavadiya, N. and Madamwar, D. (2008): Ameliorative action of cyanobacterial phycoerythrin on CCl4-induced toxicity in rats. Toxicol., 248: 59–65.

Suzuki, Y.J.; Tsuchiya, M. and Packer, L. (1993):Antioxidant activities of dihydrolipoic acid and its structural homologues. Free Radic. Res. Commun., 18: 115–122.

Taye, A. and Abdel-Raheem, I. (2012): Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against CCl4-induced liver damage. Ann. Hepatol. 11(3): 384-391.

Tietz, N.W. and Rinker, A.D. (1983): The measurement of alkaline phosphatase In: Analytical concepts in Enzymology. Honnberger, H.A. (ed.), College of

American Pathologists, USA, P.P. 195-203.

Weber, L.W.D.; Boll, M. and Stampfl, A. (2003): Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol., 33: 105–136.

Wollin, S.D. and Jones, P.J. (2003): Lipoic acid and cardiovascular disease. J. Nutr., 133: 3327-3330.

Zimmerman, M. (1983): Ethical guidelines for investigation of experimental pain in conscious animal. Pain, 16: 109-110.

الشحم حمض و لألمينوجوانيدين المحتمل الواقي التأثيركلوريد لرابع الكبدية السمية من الحد في األلفائي

البيضاء الجرذان فى الكربونبيومي عبدالفتاح , خالد إيهاب, و الله جاب فوزي إيمان شهاب محمد عالء

ابراهيم *رفعت - * : كلية الهستولوجيا و اإلكلينيكية، والسموم الشرعى الطب أقسام من

القاهرة - جامعة الطب

معمليا ويستخدم قويا بيئيا كبديا سما الكربون كلوريد رابع يعدالشوارد إنتاج على قدرته بسبب الغرض لذلك قياسي كنموذج

إلنزيم. مثبطا يعتبر األمينوجوانيدين فإن اآلخر الجانب على الحرةالتهام األلفائي الشحم حمض يستطيع بينما سنثاز أكسيد النيتريك

. الحرة الواقية الشوارد التأثيرات لدراسة البحث هذا تصميم تملرابع و أمينوجوانيدينلل الكبدية السمية ضد األلفائي الشحم حمض

البيضاء الجرذان في الكربون تقسيم .كلوريد تم الغرض ولهذاعلى جرذان ثمانية عدد منها كل ضم مجموعات خمس الى الجرذان

التالى : النحو

السالبة- 1 الضابطة المجموعةبر- 2 تجريعها تم وقد الكبدى التسمم الكربون مجموعة كلوريد ابعالمعالجة- 3 )100باألمينوجوانيدين (المجموعه / كجم .مجمالمعالجة- 4 األلفائي (المجموعه الشحم )100بحمض / كجم .مجمالمعالجة - 5 األلفائي المجموعه الشحم وحمض باألمينوجوانيدين

المذكورة الجرعات .بنفس

جرعة والخامسة والرابعة الثالثة المجموعات من كل إعطاء تمقبل أسبوعين لمدة الفم طريق عن العقاقير من يوميا واحدة

الكربون تجريعها كلوريد رابع )1( مع / الجلد تحت بالحقن كجم مل. أسبوع لمدة يوم بعد طريق يوم عن الكبدي التلف تقييم تم

. النسيجي و البيوكيميائي الفحص

الكبد وظائف في إحصائية داللة ذي تدهور وجود الى النتائج خلصتالجرذان في ملحوظة كبدية مورفولوجية تغيرات وجود مع

ب الكربون المتسممة كلوريد إلى رابع على باإلضافة األخير تأثيرالجلوتاثيون تركيز ونقص جانب من الدهون أكسدة نواتج زيادة

. اآلخر الجانب من لألكسدة المضادة اإلنزيمات تم ونشاط وقدأكبر بدرجة الباثولوجية التأثيرات ومنها التأثيرات هذه من التقليل

تناول األلفائي و األمينوجوانيدين عند الشحم عند حمض عنه معا منفردا أحدهما العالج. تناول أن الدراسة هذه من ونستنتج

/ تأثير مقاومة يمكنه األلفائي الشحم حمض أو و باألمينوجوانيدين , العقارين استخدام يمكن ولهذا الكبد على الكربون كلوريد رابع

الكبد لحماية